For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Regeneron Pharmaceuticals, Inc.’s stock clocked out at $1175.33, up 1.60% from its previous closing price of $1156.86. In other words, the price has increased by $1.60 from its previous closing price. On the day, 0.57 million shares were traded. REGN stock price reached its highest trading level at $1177.95 during the session, while it also had its lowest trading level at $1155.305.
Ratios:
To gain a deeper understanding of REGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.92. For the most recent quarter (mrq), Quick Ratio is recorded 4.62 and its Current Ratio is at 5.44. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Bernstein on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $1125.
On January 12, 2024, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform and also upped its target price recommendation from $884 to $1076.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Hold rating and target price of $800.Deutsche Bank initiated its Hold rating on November 09, 2023, with a $800 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’24 when Christine Poon bought 10,838 shares for $1156.86 per share.
MURPHY ANDREW J sold 6,363 shares of REGN for $7,337,505 on Aug 14 ’24. The EVP Research now owns 48,306 shares after completing the transaction at $1153.15 per share. On Aug 15 ’24, another insider, Bassler Bonnie L, who serves as the Director of the company, bought 756 shares for $1170.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 129562501120 and an Enterprise Value of 117759737856. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.13, and their Forward P/E ratio for the next fiscal year is 24.13. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.96. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.60 while its Price-to-Book (P/B) ratio in mrq is 4.59. Its current Enterprise Value per Revenue stands at 8.73 whereas that against EBITDA is 26.058.
Stock Price History:
The Beta on a monthly basis for REGN is 0.11, which has changed by 0.424003 over the last 52 weeks, in comparison to a change of 0.24841464 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1161.21, while it has fallen to a 52-week low of $769.19. The 50-Day Moving Average of the stock is 10.61%, while the 200-Day Moving Average is calculated to be 23.79%.
Shares Statistics:
It appears that REGN traded 450.99K shares on average per day over the past three months and 567550 shares per day over the past ten days. A total of 107.60M shares are outstanding, with a floating share count of 106.29M. Insiders hold about 3.56% of the company’s shares, while institutions hold 86.50% stake in the company. Shares short for REGN as of 1722384000 were 2010425 with a Short Ratio of 4.46, compared to 1719532800 on 2037891. Therefore, it implies a Short% of Shares Outstanding of 2010425 and a Short% of Float of 1.9199998999999999.
Earnings Estimates
The firm’s stock currently is rated by 23.0 analysts. The consensus estimate for the next quarter is $11.94, with high estimates of $13.85 and low estimates of $9.53.
Analysts are recommending an EPS of between $48.0 and $41.75 for the fiscal current year, implying an average EPS of $45.09. EPS for the following year is $48.75, with 25.0 analysts recommending between $56.82 and $41.16.
Revenue Estimates
In the current quarter, 22 analysts expect revenue to total $3.66B. It ranges from a high estimate of $3.85B to a low estimate of $3.34B. As of the current estimate, Regeneron Pharmaceuticals, Inc.’s year-ago sales were $3.36BFor the next quarter, 22 analysts are estimating revenue of $3.8B. There is a high estimate of $4.03B for the next quarter, whereas the lowest estimate is $3.48B.
A total of 25 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.55B, while the lowest revenue estimate was $13.51B, resulting in an average revenue estimate of $14.18B. In the same quarter a year ago, actual revenue was $13.12BBased on 25 analysts’ estimates, the company’s revenue will be $15.37B in the next fiscal year. The high estimate is $17.14B and the low estimate is $13.96B.
